Skip to main content
Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
17.35
+0.04 (0.23%)
At close: Mar 9, 2026, 4:00 PM EDT
17.31
-0.04 (-0.23%)
After-hours: Mar 9, 2026, 4:04 PM EDT

Avalo Therapeutics Revenue

Avalo Therapeutics had revenue of $192.00K in the twelve months ending September 30, 2025, down -76.59% year-over-year. In the year 2024, Avalo Therapeutics had annual revenue of $441.00K, down -77.08%.

Revenue (ttm)
$192.00K
Revenue Growth
-76.59%
P/S Ratio
1,669.04
Revenue / Employee
$8,348
Employees
23
Market Cap
321.20M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024441.00K-1.48M-77.08%
Dec 31, 20231.92M-16.13M-89.34%
Dec 31, 202218.05M12.65M234.40%
Dec 31, 20215.40M-1.30M-19.42%
Dec 31, 20206.70M-51.35K-0.76%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Puma Biotechnology 228.37M
XOMA Royalty 47.11M
X4 Pharmaceuticals 33.98M
Opus Genetics 14.63M
Adlai Nortye -1.35M
Revenue Rankings

AVTX News

More News